177Lu-rhPSMA-10.1 injection for Metastatic Castration Resistant Prostate Cancer
Study Summary
This trial is testing a new treatment for prostate cancer that has spread and is resistant to hormone therapy. They are testing how well it works and how safe it is.
- Metastatic Castration Resistant Prostate Cancer
- Prostate Cancer
- Urogenital Neoplasms
- Prostate Disease
Treatment Effectiveness
Effectiveness Progress
Study Objectives
3 Primary · 0 Secondary · Reporting Duration: 12 weekly intervals
Trial Safety
Safety Progress
Trial Design
4 Treatment Groups
Phase 1, Cohort A
1 of 4
Phase 1, Cohort B
1 of 4
Phase 2, Cohort 1, post-chemotherapy mCRPC
1 of 4
Phase 2, Cohort 2, Taxane-naïve mCRPC
1 of 4
Experimental Treatment
150 Total Participants · 4 Treatment Groups
Primary Treatment: 177Lu-rhPSMA-10.1 injection · No Placebo Group · Phase 1 & 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · Male Participants · 12 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Who else is applying?
What site did they apply to?
Advanced Molecular Imaging and Therapy | 100.0% |
What portion of applicants met pre-screening criteria?
Did not meet criteria | 100.0% |
Frequently Asked Questions
Is this research currently open to enrollment?
"Clinicaltrials.gov reports that this clinical trial is now open to participants; it was initially posted on the 20th of July 2022 and updated most recently on the 26th of July 2022." - Anonymous Online Contributor
To what extent is enrollment in this clinical trial being maximized?
"Affirmative, the information available on clinicaltrials.gov exhibits that this medical trial is presently recruiting patients. The initial advertisement for participation was posted on July 20th 2022 and has been updated as recently as July 26th 2022 – 150 individuals are expected from 1 research hub." - Anonymous Online Contributor